Not quite as good as if you had bought Eli Lilly at the same time (+106%), but much better than the other major GLP-1 stock, Novo Nordisk (incredibly, down 4% since the beginning of 2023)
Key GLP Compounds in Research Semaglutide (GLP-1) Studied for its role in appetite signaling and metabolic regulation pathways
The starting point coincided with the approval date of the first GLP-1 RA, exenatide (BYETTA), April 28, 2005
What it may offer, for an eligible patient: a provider-supervised pathway to GLP-1 treatment that removes the most common friction points - the months-long wait for an in-person weight management appointment, the difficulty navigating prior authorizations alone, and the lack of ongoing clinical support after an initial prescription
Best for Maximum Weight Loss Injectable GLP-1s outperform oral GLP-1s in terms of weight loss in clinical trials, but results are mixed in real-world settings